S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
ūüö® [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
ūüö® [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
ūüö® [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
ūüö® [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
ūüö® [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
ūüö® [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
ūüö® [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
ūüö® [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:HCM

HUTCHMED - HCM Stock Forecast, Price & News

$12.95
+0.82 (+6.76%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.56
‚Ėľ
$13.93
50-Day Range
$7.65
‚Ėľ
$12.97
52-Week Range
$7.39
‚Ėľ
$36.29
Volume
1.21 million shs
Average Volume
524,788 shs
Market Capitalization
$2.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

HUTCHMED MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
23.6% Upside
$16.00 Price Target
Short Interest
Healthy
1.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of HUTCHMED in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.99) to ($1.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

799th out of 1,047 stocks

Pharmaceutical Preparations Industry

388th out of 512 stocks

HCM stock logo

About HUTCHMED (NASDAQ:HCM) Stock

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HCM Stock News Headlines

See More Headlines
Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HCM Company Calendar

Today
12/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HCM
Employees
1,759
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+23.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$356.13 million
Book Value
$6.01 per share

Miscellaneous

Free Float
166,729,000
Market Cap
$2.24 billion
Optionable
Not Optionable
Beta
1.00

Key Executives

  • Mr. Chi Keung To ACGI (Age 70)
    B.Sc., BSc, M.B.A., MBA, Exec. Chairman
    Comp: $85k
  • Dr. Weiguo Su B.Sc. (Age 65)
    Ph.D., CEO, Chief Scientific Officer & Exec. Director
    Comp: $1.36M
  • Mr. Chig Fung Cheng BEc (Age 55)
    CA, CFO & Exec. Director
    Comp: $838.51k
  • Ms. Edith Shih C.S. (Age 70)
    CGP, FCS, M.A., P.E., BSE, EdM, Solicito, Company Sec. & Non-Exec. Director
    Comp: $74.3k
  • Dr. Karen Jane Atkin (Age 56)
    Exec. VP & COO
  • Mr. Kin Hung Lee M.B.A. (Age 45)
    Sr. VP of Corp. Fin. & Devel.
  • Mr. Charles George Rupert Nixon (Age 52)
    Group Gen. Counsel
  • Ms. Selina Zhang
    Sr. VP of Global HR
  • Dr. Qingmei Wang Ph.D. (Age 59)
    Sr. VP of Bus. Devel. & Strategic Alliances
  • Mr. Hong Chen (Age 52)
    Sr. VP & Chief Commercial Officer- China













HCM Stock - Frequently Asked Questions

Should I buy or sell HUTCHMED stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HCM, but not buy additional shares or sell existing shares.
View HCM analyst ratings
or view top-rated stocks.

What is HUTCHMED's stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month price objectives for HUTCHMED's stock. Their HCM share price forecasts range from $16.00 to $16.00. On average, they anticipate the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 23.6% from the stock's current price.
View analysts price targets for HCM
or view top-rated stocks among Wall Street analysts.

How have HCM shares performed in 2022?

HUTCHMED's stock was trading at $35.08 at the beginning of the year. Since then, HCM stock has decreased by 63.1% and is now trading at $12.95.
View the best growth stocks for 2022 here
.

Are investors shorting HUTCHMED?

HUTCHMED saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 2,520,000 shares, a decline of 10.3% from the October 31st total of 2,810,000 shares. Based on an average daily volume of 394,300 shares, the days-to-cover ratio is currently 6.4 days.
View HUTCHMED's Short Interest
.

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Telford Homes (TEF), AbbVie (ABBV), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Premier Oil (PMO), CRISPR Therapeutics (CRSP), AT&T (T), Johnson & Johnson (JNJ), NVIDIA (NVDA) and Weyerhaeuser (WY).

When did HUTCHMED IPO?

(HCM) raised $100 million in an initial public offering (IPO) on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

What is HUTCHMED's stock symbol?

HUTCHMED trades on the NASDAQ under the ticker symbol "HCM."

Who are HUTCHMED's major shareholders?

HUTCHMED's stock is owned by a number of retail and institutional investors. Top institutional shareholders include M&G Investment Management Ltd. (4.96%), BlackRock Inc. (2.17%), Allianz Asset Management GmbH (1.02%), Bellevue Group AG (1.02%), State Street Corp (0.69%) and AIA Group Ltd (0.27%).

How do I buy shares of HUTCHMED?

Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HUTCHMED's stock price today?

One share of HCM stock can currently be purchased for approximately $12.95.

How much money does HUTCHMED make?

HUTCHMED (NASDAQ:HCM) has a market capitalization of $2.24 billion and generates $356.13 million in revenue each year.

How many employees does HUTCHMED have?

The company employs 1,759 workers across the globe.

How can I contact HUTCHMED?

HUTCHMED's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The official website for the company is www.chi-med.com. The company can be reached via phone at 852-2121-3888, via email at ir@chi-med.com, or via fax at 852-2128-1778.

This page (NASDAQ:HCM) was last updated on 12/2/2022 by MarketBeat.com Staff